Becton Dickinson (BDX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$184.74-1.54%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · BDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 1.7% |
| Our one-year growth estimate | diamond | -11.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 13.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
BDX — President transition
Dated 2026-07-22
Executive Vice President and President of the Medical Essentials and BioPharma Systems segments — Michael D. Garrison: Michael D. Garrison intends to retire and a search for his successor is underway.
Why it matters: Earnings results will show BD's financial health and how it is doing after the spin-off.
Watch forQ2 earnings show revenue growth above 5% year over year, indicating strong performance.
Also watch forThe Q2 earnings report shows revenue growth below 0% year over year, which may signal problems.
Why it matters: The merger is expected to create a larger market presence and drive revenue growth.
Supportive ifBD reports revenue growth above mid-to-high single digits in the next earnings.
Worry ifRevenue growth drops below the expected mid-to-high single digits in the next earnings.
Why it matters: Paying off debt can make the balance sheet stronger. It can also help financial stability.
Supportive ifThe company paid off a lot of debt with the $4 billion cash.
Worry ifThere is no big debt repayment or increase in debt levels.
Why it matters: A smooth change in leadership can impact the company's plans and stability.
Watch forAnnouncement of a successor to Michael D. Garrison as President.
Also watch forA long delay in finding a new leader creates uncertainty in leadership.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$103 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $226 loss on $10,000 · 2.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,361 loss on $10,000 · 23.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Using money to pay off debt can make BD's balance sheet stronger and safer.
Supportive ifBD announces repayment of at least $1 billion in debt within six months of the Waters transaction closing.
Worry ifBD delays debt repayment or fails to provide updates on repayment plans.
Why it matters: Getting regulatory approval is key for the Waters merger. It affects future growth.
Watch forThe company got the green light for the Waters merger.
Also watch forThere is a delay or no approval for the Waters merger.
Why it matters: Management raised the full-year adjusted EPS guidance. This shows strong earnings growth.
Supportive ifQ2 adjusted EPS lands within the new guidance range of $12.52 to $12.72.
Worry ifQ2 adjusted EPS is below $12.52. This means weaker earnings performance.
Why it matters: Paying down debt can strengthen BD's balance sheet and improve financial health.
Supportive ifBD says it has reduced debt after the $4 billion cash distribution.
Worry ifDebt levels stay the same or go up after the cash distribution.
Why it matters: This investment aims to improve supply strength. It also shows long-term growth potential.
Watch forManagement lists key goals for the $2.5 billion investment in U.S. manufacturing.
Also watch forThere are no updates or delays on the investment plan. This may mean problems.
Why it matters: Completing the buyback program could show strong use of funds and more value for shareholders.
Supportive ifBD will complete at least $1 billion in share buybacks from the $2 billion plan.
Worry ifBD does not complete the buyback program as planned or cuts the buyback amount.
Why it matters: Management's guidance shows they are confident in business growth and plans.
Supportive ifManagement raises revenue growth guidance to the high end of the range.
Worry ifManagement cuts revenue growth guidance below the current range.
Why it matters: Earnings results will show how well BD is running its business after the spin-off.
Watch forBD reports Q2 earnings. They beat what analysts expected for revenue and adjusted EPS.
Also watch forBD reports Q2 earnings that fall short of analyst expectations for revenue and adjusted EPS.
Why it matters: Naming a new president can show stability in leadership and future plans.
Watch forBD names a new president before the current one retires.
Also watch forNo news on a new president before the current one retires.
Why it matters: Completing this will change BD into a focused MedTech company.
Supportive ifThe deal will close by the end of Q1 2026. All approvals will be in place.
Worry ifThe transaction faces delays or fails to close due to regulatory issues.
Why it matters: Management raised its revenue growth forecast. This shows they have ongoing momentum.
Supportive ifQ3 revenue growth reported at or above 5.4% year over year.
Worry ifQ3 revenue growth reported below 4.0% year over year.
Why it matters: Management raised the midpoint of adjusted EPS guidance. Meeting this target shows strong earnings.
Supportive ifAdjusted diluted EPS was at or above $3.23.
Worry ifAdjusted diluted EPS was below $3.00.
Why it matters: Executing the share repurchase program shows confidence in cash flow and spending.
Supportive ifThey announced more share repurchases beyond the first $2 billion.
Worry ifNo new share repurchases were announced or completed.